AT214596T - Solid compositions with a non-amorphous active ingredient and polyethylene oxide - Google Patents

Solid compositions with a non-amorphous active ingredient and polyethylene oxide

Info

Publication number
AT214596T
AT214596T AT96913593T AT96913593T AT214596T AT 214596 T AT214596 T AT 214596T AT 96913593 T AT96913593 T AT 96913593T AT 96913593 T AT96913593 T AT 96913593T AT 214596 T AT214596 T AT 214596T
Authority
AT
Austria
Prior art keywords
non
active ingredient
polyethylene oxide
solid compositions
amorphous active
Prior art date
Application number
AT96913593T
Other languages
German (de)
Inventor
Pawan Seth
Andre Stamm
Original Assignee
Pharma Pass
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
Priority to FR9504520 priority Critical
Application filed by Pharma Pass filed Critical Pharma Pass
Priority to PCT/FR1996/000574 priority patent/WO1996032097A1/en
Publication of AT214596T publication Critical patent/AT214596T/en
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=9478138&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AT214596(T) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52Purines, e.g. adenine
    • A61K31/522Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic, hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • A61K31/195Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid, pantothenic acid
    • A61K31/198Alpha-aminoacids, e.g. alanine, edetic acids [EDTA]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/21Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/216Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/275Nitriles; Isonitriles
    • A61K31/277Nitriles; Isonitriles having a ring, e.g. verapamil
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/335Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/401Proline; Derivatives thereof, e.g. captopril
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/44221,4-Dihydropyridines, e.g. nifedipine, nicardipine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K31/55Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/554Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one sulfur as ring hetero atoms, e.g. chlothiapine, diltiazem
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/64Sulfonylureas, e.g. glibenclamide, tolbutamide, chlorpropamide
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2022Organic macromolecular compounds
    • A61K9/2031Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
AT96913593T 1995-04-14 1996-04-15 Solid compositions with a non-amorphous active ingredient and polyethylene oxide AT214596T (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
FR9504520 1995-04-14
PCT/FR1996/000574 WO1996032097A1 (en) 1995-04-14 1996-04-15 Solid compositions containing polyethyleneoxide and a non-amorphous active principle

Publications (1)

Publication Number Publication Date
AT214596T true AT214596T (en) 2002-04-15

Family

ID=9478138

Family Applications (1)

Application Number Title Priority Date Filing Date
AT96913593T AT214596T (en) 1995-04-14 1996-04-15 Solid compositions with a non-amorphous active ingredient and polyethylene oxide

Country Status (6)

Country Link
EP (1) EP0830129B1 (en)
AT (1) AT214596T (en)
AU (1) AU5652796A (en)
CA (1) CA2218054C (en)
DE (2) DE69619979T2 (en)
WO (1) WO1996032097A1 (en)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HU9902351A3 (en) * 1998-07-22 2001-01-29 Pharma Pass L L C Irvine Solid compositions containing metoprolol and process for producing the same
EP0974343B1 (en) * 1998-07-22 2004-09-29 Pharma Pass II LLC Process for manufacturing a solid metoprolol composition
US5972389A (en) * 1996-09-19 1999-10-26 Depomed, Inc. Gastric-retentive, oral drug dosage forms for the controlled-release of sparingly soluble drugs and insoluble matter
WO1998019708A2 (en) * 1996-11-04 1998-05-14 Union Carbide Chemicals & Plastics Technology Corporation Method for enhancing the solubility of substantially water-insoluble compounds
US6635280B2 (en) 1997-06-06 2003-10-21 Depomed, Inc. Extending the duration of drug release within the stomach during the fed mode
ES2248908T7 (en) * 1997-06-06 2014-11-24 Depomed, Inc. Dosage forms of drugs orally and gastric retention for continued release of highly soluble drugs
EP0987020A1 (en) * 1998-09-04 2000-03-22 Pharma Pass LLC Metoprolol composition and processes for manufacturing the same
WO2001010466A1 (en) * 1999-08-04 2001-02-15 Yamanouchi Pharmaceutical Co., Ltd. Stable medicinal compositions for oral use
CA2441064A1 (en) * 2001-03-16 2002-09-26 Andrx Corporation Controlled release sulfonylurea formulation
US7612112B2 (en) 2001-10-25 2009-11-03 Depomed, Inc. Methods of treatment using a gastric retained gabapentin dosage
CA2409552A1 (en) 2001-10-25 2003-04-25 Depomed, Inc. Gastric retentive oral dosage form with restricted drug release in the lower gastrointestinal tract
TWI312285B (en) 2001-10-25 2009-07-21 Depomed Inc Methods of treatment using a gastric retained gabapentin dosage
AU2003240213A1 (en) * 2002-06-24 2004-01-06 Ranbaxy Laboratories Limited Process for the preparation of robust formulations of valacyclovir hydrochloride tablets
US7442387B2 (en) * 2003-03-06 2008-10-28 Astellas Pharma Inc. Pharmaceutical composition for controlled release of active substances and manufacturing method thereof
SA2709B1 (en) 2006-08-25 2011-07-20 بيورديو فارما إل. بي. Tamper Resistant Oral Pharmaceutical Dosage Forms Comprising an Opioid Analgesic
US8071119B2 (en) 2007-05-14 2011-12-06 Sustained Nano Systems Llc Controlled release implantable dispensing device and method
US20090176882A1 (en) 2008-12-09 2009-07-09 Depomed, Inc. Gastric retentive gabapentin dosage forms and methods for using same
US20130143867A1 (en) 2011-12-02 2013-06-06 Sychroneuron Inc. Acamprosate formulations, methods of using the same, and combinations comprising the same
WO2014197744A1 (en) 2013-06-05 2014-12-11 Synchroneuron, Inc. Acamprosate formulations, methods of using the same, and combinations comprising the same

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4764378A (en) * 1986-02-10 1988-08-16 Zetachron, Inc. Buccal drug dosage form
US5273758A (en) * 1991-03-18 1993-12-28 Sandoz Ltd. Directly compressible polyethylene oxide vehicle for preparing therapeutic dosage forms

Also Published As

Publication number Publication date
CA2218054A1 (en) 1996-10-17
WO1996032097A1 (en) 1996-10-17
DE69619979D1 (en) 2002-04-25
AU5652796A (en) 1996-10-30
DE69619979T2 (en) 2002-11-21
EP0830129B1 (en) 2002-03-20
EP0830129A1 (en) 1998-03-25
CA2218054C (en) 2005-10-18

Similar Documents

Publication Publication Date Title
DE69425782T2 (en) Hyterosalpingographie and selective salpingography
DE69422523T2 (en) Anti-gp39 antibodies and their uses
DE69421634T2 (en) Water-absorbing composition and material
DE69324373D1 (en) ELECTRIC toothbrush and toothbrush
DE69331496T2 (en) Powder coating and use
DE69316326T2 (en) Emulsifying agents, emulsifying composition and powdery Zusammensetsung
DE69530939D1 (en) Foamable formulation and foamable
DE69408304T2 (en) Lipid-polymer conjugates and liposomes
DE69614424T2 (en) Stretchable band and absorbent article
DE69331583D1 (en) and compositions produced therefrom intra-ocular lenses polymeric
DE69715643T2 (en) Adhesives preparation and their use
DE69427918D1 (en) Hair care products
DE69228501D1 (en) New packaging systems and aqueous formulations
DE69417879D1 (en) Dehydrogenierungsverfahren and geraet here for
DE69415163D1 (en) ZUZAMMENSETUNG CONTAINING 1,1,1,2,3,4,4,5,5,5, -DECAFLUORPENTAN AND n-PROPANOL
DE69332875D1 (en) A hair cosmetic composition
DE59609305D1 (en) Epothilone derivatives and their preparation
EE9400394A (en) Spirocycloalkyl-substituted atsetidinoonid cholesterol-lowering active ingredients
DE69127708D1 (en) Container closure and container
DE69414225T2 (en) Make-up composition in Maskaraform containing at least a wax and a pseudo-latex
DE69722257D1 (en) Drug delivery and packaging
AT186265T (en) Pasteurizable plastic containers
FI973471A (en) Pyrazol-4-yylibentsoyylijohdoksia and their use as herbicides
DE69314253D1 (en) The microparticle composition and preparation thereof
AT207374T (en) Implant and application device